Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs

For years now Roche has dominated the very top circle of Big Pharma R&D, investing more than $8 billion a year in drug development through a global network of research centers concentrated at Chugai, gRED in South San Francisco and pRED out of Basel.